New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol

Certolizumab pegol (CZP) is a new drug from the group of tumor necrosis factor a inhibitors. The efficacy and safety CZP in the treatment of rheumatoid arthritis (RA) have been studied in the international 52-week RAPID-1 and 24-week RAPID-2 clinical trials that studied the use of CZP in combination...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Dmitry Evgenyevich Karateev, E L Nasonov, L N Denisov, M L Stanislav, E Yu Panasyuk, I A Andrianova, V I Mazurov, E S Zhugrova, Yu P Uspensky, L N Belousova, E P Ilivanova, G K Matsiyevskaya, G P Aurtyunov, K A Lytkina, R S Saikovsky, V N Ardashev, E V Zhilyaev, N I Korshunov
Médium:	Artigo
Jazyk:	Russo
Vydáno:	IMA PRESS LLC 2012-04-01
Edice:	Научно-практическая ревматология
Témata:	rapid 1 rapid 2 certolizumab pegol rheumatoid arthritis randomized clinical trial
On-line přístup:	https://rsp.mediar-press.net/rsp/article/view/1161
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!